Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ResMed's interest expense for the
three
months ended in Mar. 2026 was MXN 0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ResMed's Operating Income for the
three
months ended in Mar. 2026 was MXN 9,013 Mil. ResMed's Interest Expense for the
three
months ended in Mar. 2026 was MXN 0 Mil.
GuruFocus does not calculate ResMed's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ResMed (MEX:RMD) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
ResMed's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
GuruFocus does not calculate ResMed's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
ResMed Interest Expense Historical Data
* Premium members only.
The historical data trend for ResMed's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a Interest Expense of MXN0 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on ResMed and its competitors.
Is ResMed's Interest Expense too high?
ResMed's current Interest Expense is MXN0 Mil. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Interest Expense compare to MDLN and WST?
ResMed's Interest Expense of MXN0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on ResMed and its competitors. ResMed's current Interest Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,459.23, compared to a current price of MXN3,419.00 — trading 23.3% below its estimated fair value. The current Interest Expense is MXN0 Mil. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Interest Expense is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,419.00 is trading 23.3% below its estimated GF Value™ of MXN4,459.23.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
Interest Expense: MXN0 Mil
GF Value™: MXN4,459.23 vs. price of MXN3,419.00 (23.3% below fair value)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
